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ABSTRACT
Acute leukemia (AL) is the most common hematological malignancy requiring intensive care unit
(ICU) management. Data on long-term survival are limited. This is a post hoc analysis of the pro-
spective multicenter data from France and Belgium: A Groupe de Recherche Respiratoire en
Reanimation Onco-Hematologique [A Research Group on Acute Respiratory Failure in Onco-
Hematological Patients (French)] Study, to identify determinants of 1-year survival in critically ill
AL patients. A total of 278 patients were admitted in the 17 participating ICUs. Median age was
58 years and 70% had newly diagnosed leukemia. ICU mortality rate was 28.6 and 39.6% of the
patients alive at 1 year. Admission for intensive monitoring was independently associated with
better 1-year survival by multivariate analysis. Conversely, relapsed/refractory disease, secondary
leukemia, mechanical ventilation and renal replacement therapy were independently associated
with 1-year mortality. This study confirms the impact of organ dysfunction on long-term survival
in ICU patients with AL. Follow-up studies to assess respiratory and renal recovery are warranted.
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Introduction
The short-term outcome of patients with acute leuke-
mia (AL) has been extensively studied. Lower fibrino-
gen levels, comorbidity index and sepsis are known
risk factors for clinical deterioration leading to inten-
sive care unit (ICU) admission in patients with AL [1,2].
More than 60% of the patients with acute myeloid leu-
kemia who require intensive care survive to ICU or
hospital discharge [3–5]. Several predictive factors
have been suggested: mechanical ventilation, poor
performance status, comorbidity index, allogeneic
hematopoietic stem cell transplant (HSCT), organ dys-
function score, cardiac arrest, acute respiratory failure,
malignant organ infiltration and invasive aspergillosis
were associated with higher mortality [3,6–8].
However, data concerning the long-term survival of
critically ill AL patients after ICU discharge is still scarce
[4,5,8] and larger population and multicenter studies
are needed to evaluate outcomes and predictors.
Firstly, there is an urgent need of multicenter outcome
studies on patients with AL who require ICU admis-
sion. The main data are limited to small, retrospective,
single-center studies with a mixed cohort of critically
ill patients with all forms of hematological malignan-
cies. Secondly, the impact of the characteristics of the
underlying malignancy versus acute illness factors on
the long-term survival needs to be clarified. Even
though earlier studies showed that long-term survival
was mainly predicted by hematologic prognostic fac-
tors [5,9], more recent studies suggest that factors
related to the acute illness may be the strongest pre-
dictors [6,7]. Thirdly, the impact of early ICU admission
on the long-term outcome remains unclear. Even
though earlier studies on hematological patients did
not show an impact on ICU mortality [10,11], a better
survival for patients admitted more rapidly to the ICU
was shown more recently [3]. The identification of
prognostic factors of long-term survival can provide
useful information for hematologists and intensivists
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that can facilitate discussions of prognosis with
patients and families.
The aims of this study were to describe the long-
term outcome of patients with AL admitted to critical
care and investigate predictive factors of outcome
using a secondary analysis based on a prospective
multicenter cohort study of patients with hemato-
logical malignancies admitted to the ICU.
Methods
Patients and study design
The Prospective Multicenter Data from France and
Belgium: A Groupe de Recherche Respiratoire en
Reanimation Onco-Hematologique (A Research Group
on Acute Respiratory Failure in Onco-Hematological
Patients) Study was a prospective, multicenter study
that recruited 1011 patients with hematological malig-
nancies admitted to critical care in France and
Belgium at 17 tertiary centers from January 2010 to
May 2011 in a period of 16 months. The details of the
study have been previously reported [3]. This study
was primarily designed to evaluate prognostic factors
of hospital discharge as well as maintenance of cancer
chemotherapy, disease control and quality of life after
ICU discharge. For the present study, only those 351
patients with AL were considered eligible. Inclusion cri-
teria were a diagnosis of either AML (acute myeloid
leukemia) or ALL (acute lymphoblastic leukemia) as
defined by the World Health Organization. This
included: 1) patients who were newly diagnosed hav-
ing not yet received chemotherapy; 2) patients under-
going or having just received either remission
induction or post-remission therapy; 3) patients with
refractory or relapsing AL undergoing salvage treat-
ment. HSCT recipients were excluded. A total sample
of 278 patients, corresponding to 27.5% of the original
cohort, was analyzed (Figure 1).
Data collection and definitions
The database included data collected prospectively
and daily by study investigators from admission to day
28: age, gender, comorbidities according to the
Charlson score, performance status, type of malig-
nancy, disease status, bone marrow transplant status,
neutropenia, reason for admission, severity of illness
[according to (Sequential Organ Failure Assessment)
SOFA score], type of organ support (mechanical venti-
lation, noninvasive ventilation, renal replacement ther-
apy and vasopressors) and microbiology. Vital status at
one year was examined using both medical records
and telephone interviews by a trained social worker.
Newly diagnosed malignancies were defined as diag-
nosed within the past four weeks. Secondary leukemia
included patients with prior exposure to cytotoxic
therapy and/or radiotherapy for a malignant or non-
malignant disease and patients that developed AL
after a myelodysplastic syndrome or myeloproliferative
neoplasm. Cytogenetic and molecular genetic risk
were classified according to European LeukemiaNet
(ELN) guidelines 2010 [12]. Admission for intensive
monitoring was considered for patients with either
high-risk lysis syndrome (hyperleukocytosis leukemia),
bleeding or arrhythmia or rapid deterioration based on
detected abnormalities in vital signs. Neutropenia and
hyperleukocytosis were defined as leukocyte cell count
<0.5x109/L and 50x109/L, respectively.
Statistical analysis
Frequencies and measures of central tendency
(median and interquartile range (IQR)) were used to
describe categorical and continuous variables, respect-
ively. Univariate logistic regression analyses were per-
formed to identify hematologic and ICU-related factors
that might predict ICU and 1-year mortality. Factors
that were considered significant in the univariate anal-
yses were selected for a multivariate binary logistic
regression with stepwise backward selection.
Cumulative survival estimates, Kaplan-Meier curves
and hazard ratio point estimates for those patients
1011 paents included in the original study
351 with acute leucemia (34,7%)
275 acute myeloid leukemia
76 acute lymphoblasc leukemia
73 alloHSCT278 (27,5%) non-alloHSTC
223 AML
55 ALL
199 (71,6%) discharged
alive from the ICU
174 (62,6%) discharged alive 
from the hospital
109 (39,2%) alive at 1-year
25 (9%) los o follou-up
40 (14,4%) deaths during the ﬁrst year
1 (0,4%) los o follou-up
24 (8,6%) hospital deaths
79 (28,4%) ICU deaths
Figure 1. Patients included in the original Groupe de
Recherche Respiratoire Reanimation Onco-Hematologique [A
Research Group on Acute Respiratory Failure in Onco-
Hematological Patients (French)] Study and subpopulation
included in the present secondary analysis. alloHSCT: allogen-
eic hematopoietic stem cell transplant; ICU: intensive care unit.
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who survived ICU stay were performed. A two-tailed
p value  .05 was considered statistically significant.
All statistical analyses were performed using statistical
software SPSSVR 24.0 for Windows.
Results
Patient characteristics
Our final cohort included 278 adult patients diagnosed
with AL that were admitted to critical care. Their
median age was 58 years (IQR 44–66.2 years) and
there were 160 (57.6%) male patients. Most patients
had a good performance status (2). Eighty percent
had a diagnosis of AML and the remaining 20% had a
diagnosis of ALL with the majority presenting with
newly diagnosed leukemia. Fifty-seven patients had a
secondary leukemia. Data on cytogenetic abnormalities
were available in a subset of 117 patients with AML,
of which 53, 32 and 32 were stratified, respectively, as
an intermediate, low and high-risk leukemia. Details of
demographic and clinical features of the 278 patients
are shown in Table 1. Fifty-two patients (18.4%) were
admitted to the ICU directly from the emergency
department. The remaining 226 patients were admit-
ted from the hospital ward with a median time inter-
val between hospital and ICU admission of 12 days
(2–24). The primary indication for ICU admission was
severe sepsis/septic shock (37.8%) followed by inten-
sive monitoring (23.4%). Half of the patients had dys-
function in multiple organ systems at the time of
admission and only 34 patients (12.2%) did not pre-
sent any organ dysfunction. Neutropenia was docu-
mented in 115 patients. During the ICU stay, 46.8, 45.7
and 26.6%, respectively, of the patients required,
mechanical ventilation, vasoactive drugs and renal
replacement therapy. No life-supporting intervention
was required in 74 patients (26.7%). The median ICU
length of stay (LOS) was five days (3–11) and the
median hospital LOS was 20 days (9.5–34.5).
Outcomes
A total of 103 patients died during hospitalization, of
which 79 (28.4%) died in the ICU and the remaining
24 (8.6%) died in the ward (Figure 1). Among the 174
patients discharged alive from the hospital, 109 were
alive at 1-year corresponding to 39.2% of the cohort.
The ICU-mortality of AML and ALL patients was 31.8
and 14.5%, respectively. The 1-year mortality of AML
and ALL patients was 54.7 (12 missing) and 38.1% (14
missing), respectively. After excluding the 65 patients
admitted for intensive monitoring, ICU mortality rate
was 31% and 1-year survival rate was 34.7%.
Table 1. Patient demographics and clinical characteristics.
Number of patients (% or IQR)
Age, years
Median, IQR 58 (44–66.2)
>60 years 123 (44.2)
Male gender 160 (57.6)
Leukemia type
Acute myeloid leukemia 223 (80.2)
M3 and M3v 24 (8.6)
M4 and M5 83 (29.8)
ELN 2010 risk classification 32 (11.5)
Favorable 53 (29)
Intermediate 32 (11.5)
Adverse 106 (37.8)
Unknown 55 (19.8)
Acute lymphoblastic leukemia 7 (2.5)
Philadelphia (þ) 57 (20.5)
Secondary leukemia
Disease status
Newly diagnosed 197 (70.9)
Relapsed/Refractory 49 (17.6)
Remission 32 (11.5)
Comorbidities
Hypertension 81 (29.1)
Diabetes 29 (10.4)
Ischemic heart disease 27 (9.7)
Hepatic 24 (8.6)
Renal 18 (6.5)
COPD 9 (3.2)
HIV/AIDS 4 (1.4)
Reasons for admission
Severe sepsis/septic shock 105 (37.8)
Monitoring 65 (23.4)
Acute respiratory failure 57 (20.5)
Digestive 10 (3.6)
Coma 10 (3.6)
Cardiac arrest 10 (3.6)
Non-septic shock 6 (2.2)
Acute renal injury 5 (1.8)
Bleeding 4 (1.4)
Miscellaneous 6 (2.2)
Conditions of admission
Time between hospital and ICU admission
Median, days 6 (1–21.5)
<24h 61 (21.9)
Direct admission to the ICU 52 (18.7)
Neutropenia 68 (24.5)
Hyperleukocytosis 18 (16.5)
SOFA score, median 5 (3.8–8)
Charlson comorbidity index, median 4 (2–5)
Performance status 2 243 (83.8)
Organ failure
Respiratory 166 (59.7)
Hemodynamic 106 (38.1)
Coagulation 75 (27)
Renal 72 (25.9)
Hepatic 20 (7.2)
Multiorgan 150 (54)
Outcomes
ICU survival 199 (71.6)
Hospital survival 174 (62.6)
90-day survival 156 (56.1)
360-day survival 109 (39.2)
Treatments in the ICU
Antibiotics 256 (92.1)
Ventilation
Mechanical 130 (46.8)
Non-invasive 86 (30.9)
Renal replacement therapy 74 (26.6)
Amines 127 (45.7)
Infections identified in the ICU
Bacterial 67 (24.1)
Gram positive 18 (6.5)
Gram negative 49 (17.6)
Fungal 25 (9)
COPD: chronic obstructive pulmonary disease; ELN: European Leukemia
Net; HIV/AIDS: human immunodeficiency virus/acquired immunodeficiency
syndrome; ICU: intensive care unit; IQR: interquartile range; SOFA:
Sequential Organ Failure Assessment.
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Comparing outcomes according to the status of the
AL at admission, patients in remission showed a sig-
nificantly better short and long-term survival (Table 2).
Prognostic factors
Mechanical ventilation and increasing SOFA were sig-
nificantly associated with higher ICU mortality (Table
3). The most important predictive factors of 1-year
mortality were disease status and secondary leukemia
(Table 4). Patients with relapsed/refractory disease
were almost four times more likely to have died 1-year
after ICU admission than the other patients. Patients
with secondary leukemia were 2.41 times more likely
to have died 1-year after ICU admission. Age and the
type of AL showed no association with the risk of
Table 3. Univariate and multivariate predictors of ICU mortality.
ICU mortality
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Demographics
Age 1.02 1–1.03 .074 –
Leukemia factors
Secondary leukemia 4.09 2–8.37 .000 2.26 0.95–5.34 .06
ALL versus AML 2.74 1.23–6.11 .013 2.18 0.80–5.97 .13
Disease status
Relapsed/Refractory 1.78 0.94–3.40 .079 0.42 0.12–1.54 .19
Remission 0.33 0.11–0.96 .042 – –
Leukocytosis 0.97 0.53–1.78 .920 – –
Conditions of admission
Multiorgan dysfunction 2.14 1.24–3.7 .006 0.87 0.40–1.86 .71
SOFA 1.28 1.18–1.38 .000 1.15 1.04–1.27 .01
Neutropenia 1.27 0.75–2.15 .370 – – –
Charlson Index 1.12 0.99–1.26 .072 – – –
Sepsis 0.81 0.47–1.39 .437 – – –
Direct admission to ICU 0.62 0.30–1.29 .201 – – –
Intensive monitoring 0.56 0.28–1.09 .088 – – –
Treatments in the ICU
Mechanical ventilation 25.01 10.86–57.58 .000 12.63 4.77–33.42 <.01
Vasoactive drugs 9.21 9.87–17.41 .000 2.01 0.81–4.98 .13
RRT 3.46 1.96–6.12 .000 2.09 0.96–4.55 .06
Infection acquired in ICU 2.52 1.313–4.84 .005 0.62 0.27–1.44 .27
Bacterial 0.62 0.15–1.22 .166 – – –
Candida 2.58 0.51–13.06 .252 – – –
Aspergillus 2.43 0.95–6.23 .065 – – –
ICU LOS 1 1.00–1.02 .796 – – –
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ICU: intensive care unit; LOS: length of stay; RRT:
renal replacement therapy; SOFA: Sequential Organ Failure Assessment; OR: odds ratio; 95% CI: 95% class interval.
Table 2. Survival rates according to disease status at ICU
admission.
Newly diagnosed,
n¼ 197
R/R,
n¼ 49
Remission,
n¼ 32a
ICU mortality 56 (28.4) 19 (38.8) 4 (12.5)b
1-Year mortality 99 (54.4)c 35 (83.3)d 9 (32.1)e
ICU: intensive care unit; R/R: relapsed/refractory.
aComplete remission (n¼ 29) and partial remission (n¼ 3).
bRemission vs. R/R, p¼ .01.
cRemission vs. Newly diagnosed, p¼ .04.
dR/R vs. Newly diagnosed, p< .01.
eRemission vs. R/R, p< .01.
Table 4. Univariate and multivariate predictors of 1-year
mortality.
1-year mortality
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Demographics
Age 1.03 1.01–1.05 .000 1.01 0.99–1.04 .159
Leukemia factors
Disease status
Relapsed/refractory 4.22 2.01–11.11 .000 3.95 1.48–10.58 .01
Remission 0.32 0.14–0.74 .007 0.40 0.15–1.05 .63
Secondary leukemia 4.09 2.00–8.37 .000 2.41 1.09–5.32 .03
ALL versus AML 1.31 0.67–2.55 .436 – – –
Conditions of admission
Multiorgan failure 1.61 0.97–2.66 .065 – – –
Charlson Index 1.32 1.15–1.52 .000 1.19 0.97–1.45 .90
Direct admission to ICU 1.25 0.66–2.38 .489 – – –-
SOFA 1.16 1.08–1.25 .000 1.04 0.95–1.49 .38
Sepsis 1.04 0.76–2.18 .317 – – –
Neutropenia 1.04 0.63–1.72 .887 – – –
Intensive monitoring 0.45 0.25–0.81 .008 0.46 0.21–1.00 .05
Treatments in the ICU
Mechanical ventilation 3.43 2.03–5.80 .000 2.37 1.12–5.04 .03
Vasoactive drugs 3.05 1.81–5.15 .000 1.33 0.60–2.96 .48
RRT 2.44 1.34–4.47 .004 2.95 1.35–6.41 .01
Nosocomial infection 1.58 0.78–3.18 .201 – – –
Aspergillus 3.08 0.99–9.55 .052 – – –
Bacterial 0.95 0.37–2.45 .916 – – –
Candida 0.32 0.04–2.92 .314 – – –
ICU LOS 1.00 0.94–1.02 .830 – – –
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ICU:
intensive care unit; LOS: length of stay; RRT: renal replacement therapy;
SOFA: Sequential Organ Failure Assessment; OR: odds ratio; 95% CI: 95%
class interval.
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Figure 2. Cumulative survival according to independent predictive factors in 164 ICU survivors who could be evaluated: (A) dis-
ease status; (B) type of leukemia; (C) intensive monitoring; (D) mechanical ventilation and (E) renal replacement therapy.
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1-year mortality. Patients admitted strictly for intensive
monitoring were twice as likely to be alive at 1-year.
Among ICU factors, mechanical ventilation and renal
replacement therapy (RRT) were also associated with
an increased risk of 1-year mortality.
Figure 2 displays 1-year cumulative survival among
those patients who survived ICU stay according to
independent predictive factors. Disease status and
type of leukemia were major determinants of 1-year
survival. Additionally, patients who were admitted for
intensive monitoring also showed a lasting survival
benefit. Mechanical ventilation did not show a statis-
tically significant impact on the outcome. Post-ICU sur-
vival at 1-year in patients that received and not
received RRT was nearly equivalent.
Discussion
In the past 20 years, there has been a shift in our
thinking about ICU support in patients with AL. Early
studies discouraged ICU admission based on the poor
outcomes presented by those patients after ICU dis-
charge. Following advances in life-sustaining therapies
and close collaboration between hematologists and
intensivists, recent studies have presented a more
optimistic view of the impact of ICU admission and
nowadays, unrestricted ICU support can be recom-
mended for a large proportion of patients with all
types of hematological malignancies. However,
patients with AL admitted to ICU still exhibit signifi-
cantly higher mortality rates when compared with
patients who do not require intensive care [1,2,13].
Published studies have focused on short-term out-
comes and multicentric studies describing the long-
term survival of patients with AL are scarce. For this
reason, we performed a post hoc analysis of patients
with AL admitted to critical care. The main strengths
of the present study are: (1) patients were treated
over a time-span of 16 months in which the standard
treatment was not substantially modified; (2) the
study population was treated in 17 international
centers; (3) data were collected prospectively in the
original study and (4) robust statistical analyses were
used to identify relevant variables related to the
long-term outcome.
In our multicenter cohort of patients with AL
admitted over a 16-month period to intensive care,
62.6% of the patients were discharged alive from the
hospital and approximately two in three of them
remained alive at 1-year. Our hospital mortality rate
approximates that of the original cohort of 1011
patients with hematological malignancies (60.8%).
Additionally, no significant impact on mortality rate
of AML compared to ALL was observed. These results
are in line with an increasing number of studies
showing that the nature of the hematological malig-
nancy does not influence the outcome [14–16]. Our
ICU mortality and 1-year survival rates are similar to
those reported form other western countries. An ICU
mortality rate of 33.7% and a 1-year survival rate of
41.3% were reported from Australia, in a retrospective
study that assessed the outcome of 505 patients
with newly diagnosed AML admitted to two teaching
hospitals during a 12-year period [8]. Retrospective
single-center studies that included HSCT recipients
(representing 12-13% of those cohorts) have revealed
similar ICU mortality rates but lower 1-year survival
rates, ranging from 25–33.7% [4,5]. Even though allo-
geneic HSCT patients may remain a subpopulation
with a lower long-term survival, the outcome of
those patients who require ICU level has improved
considerably. In opposition to the overall western
standard, ICU mortality rates remain very high in
Asian countries, with the highest mortality rate
shown in Korea (84.1%) [17].
Not surprisingly, our ICU mortality was mainly pre-
dicted by severity scores and the need for mechanical
ventilation and RRT. Indeed, mechanical ventilation
was the main determinant of ICU survival with an
odds ratio (OR) for mortality of 12.63 (95% CI(95%
class interval) 4.77–33.42). Among those patients sur-
viving ICU, subjects who needed mechanical ventila-
tion or received RRT no longer manifested an
increased risk of death. The observed decrease in sur-
vival may attenuate after ICU discharge, but this find-
ing needs further investigation. The SOFA scoring
system was identified as a useful measure of the
patient severity of acute illness corroborating data
suggesting that it is the most adequate in patients
with hematological malignancies [18]. Of most import-
ance, admission of patients for intensive monitoring
was associated with a significantly better long-term
survival. Disease, patient, organizational and technical-
related factors may have contributed to this effect.
There is growing evidence that early intervention is
particularly important for short-term outcomes of
hematological patients. Identification of deteriorating
patients in the ward and rapid response by an expert
team leads to a decrease in the number of organ fail-
ures at ICU admission [10,11]. The median SOFA score
of our cohort was inferior to other groups [4,8]. Our
group showed previously that onco-hematological
patients admitted earlier to the ICU benefit from a sig-
nificantly decreased ICU mortality [3]. The results of
our study suggest that the favorable impact of early
intervention is perpetuated into the first year after ICU
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admission, corroborating growing evidence of the last-
ing impact of ICU or hospital factors on the survival of
onco-hematological patients admitted to intensive
care [6,7,19].
Disease status is a classical AL prognostic factor and
was the main determinant of 1-year mortality. Other
studies have reported similar findings [4–7], even
though the proportion of patients with relapsed/refrac-
tory disease in our study (17.4%) was lower compared
to most of them. Both the short and the long-term
mortality are lower for patients in remission and are
higher for those with refractory/relapsed disease.
Although the prognosis of adult patients with AL who
relapse is poor, approximately 10% of patients with
ALL [20] and 20–30% of patients with AML [21,22]
may become long-term survivals. Additionally, it has
been shown that AML patients who achieve complete
remission only after a second cycle of induction have
the same long-term outcome as patients with com-
plete blast clearance after the first cycle of induction
[23]. Thus, patients should not be denied admission to
the ICU based exclusively on the presence of relapsed/
refractory disease because carefully selected patients
(patients undergoing reinduction for nonresponse and
patients with a related/unrelated matched donor avail-
able) may benefit from intensive care. This requires an
interdisciplinary approach that includes hematologists,
intensivists, the patient and his/her relatives. Among
the 49 patients with relapsed/refractory disease, 30
(61.2%) were discharged alive from the ICU and 23.3%
of them (seven patients) were still alive at 1-year.
Secondary leukemia is a broad term that includes
patients with prior exposure to cytotoxic therapy and/
or radiotherapy for a malignant or nonmalignant dis-
ease and patients that develop AL after a myelodys-
plastic syndrome or myeloproliferative neoplasm [24].
It is more extensively characterized in AML represent-
ing up to 25% of newly diagnosed cases compared to
approximately 2% of newly diagnosed ALL [25].
Patients with secondary leukemia did significantly
worse compared to de novo AL. Even though second-
ary leukemia is associated with factors that confer a
poor prognosis such as older age, high-risk cytogenet-
ics and poor response to standard chemotherapy
[24–26], our study suggests that, in patients admitted
to the ICU, it has a striking and independent effect on
survival.
Age was not an independent predictor of long-term
mortality suggesting that patients with AL may benefit
from critical care independent of their age. A recent
retrospective study focusing on the outcomes of older
(60 years old) AML patients following an ICU admis-
sion showed that a substantial proportional of these
patients are admitted to the ICU and benefit from crit-
ical care, in particular those who lack multi-organ dys-
function [27]. Cytogenetics is an important factor
whose prognostic impact remains unclear to the crit-
ical care provider. The karyotype of the leukemia cells
is the strongest predictor factor across the landscape
of AML treatment. Cytogenetics affects response to
induction, relapse rates, success after transplant and
overall survival [28–31]. Even though earlier studies on
patients with AML admitted to intensive care identified
AML cytogenetic risk groups as an independent pre-
dictor of survival after ICU discharge [8,32], recent
studies, following recent risk stratification models,
found no significant association between survival and
cytogenetics [1,6,19]. Prospective studies are needed
to clarify the association of molecular genetics and
long-term survival in hematological patients admitted
to the ICU.
Our study has several limitations. Firstly, a mixed
population of patients with AML or ALL was
included. The prognosis and treatment for those two
malignancies were different and there were no
details on the type of chemotherapy. However, we
included mostly patients with newly diagnosed leu-
kemia before treatment. Secondly, we could not
evaluate well-known prognostic factors such as
molecular genetics which could be of importance for
prognostication of AML according to recently pub-
lished ELN 2017 guidelines [33]. Furthermore, our
collection of data was limited to information avail-
able in the database and though efforts were made
to obtain complete information, data were missing
for some patients. Finally, the generalizability of our
results may be limited by a possible bias concerning
hospital and ICU organizational factors which influ-
ence significantly the outcome of critically ill hema-
tological patients [34,35]. The tertiary nature of the
participating centers, the presence of a full-time
intensivist and hematologist, a nurse-to-bed ratio of
1:2.5 and case-volume may have skewed the results
towards a more positive outcome.
In summary, this post hoc analysis of patients with
AL admitted to intensive care showed an ICU mortality
rate of 28.4% and a 1-year survival rate of 39.6%. The
long-term outcome was mainly determined by the sta-
tus of the AL. Even though the severity of acute illness
and ICU or hospital variables mainly predicted the
short-term outcome, these associations seem to last
up to 1-year. Our results primarily confirm previous
publications and reinforce the importance of formal
and informal exchanges between hematologists and
intensivists to delineate the optimal treatment strategy
of critically ill AL patients.
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